Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
用于监测癌症耐药性的功能光学相干断层扫描
基本信息
- 批准号:8307913
- 负责人:
- 金额:$ 23.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:Blood VesselsCancer PatientCaringCellsClinicalCombined Modality TherapyDoseDrug FormulationsDrug resistanceERBB2 geneEnvironmentFutureGrowthHER2 inhibitionHumanImageImaging TechniquesInstructionKineticsMalignant NeoplasmsMetabolicMethodsMicroscopeMicroscopyMolecularMonitorMusOptical Coherence TomographyPenetrationPharmaceutical PreparationsPharmacodynamicsPre-Clinical ModelPreclinical Drug EvaluationReceptor CellReceptor InhibitionResolutionScheduleSignal TransductionStructureTechniquesTechnologyTherapeuticTranslatingTrastuzumabWorkbevacizumabcancer therapycellular imaginghemodynamicsimaging modalityin vivomolecular imagingnovelpre-clinicalreceptor expressionresponsesuccesstherapeutic targettumortumor growth
项目摘要
Molecular signaling is a critical therapeutic target in cancer, and molecular therapeutics have achieved some
success in treating a variety of cancers. However, our incomplete l^nowledge of pharmacodynamic effects in
vivo limits the success of these molecular therapies. We have recently developed a new molecular imaging
technique, photothermal optical coherence tomography (OCT), that extends the penetration depth of high
resolution molecular Imaging beyond the microscopy limit. The current proposal will further develop
photothermal OCT for in vivo imaging of cell receptors, and will combine this new technique with the
hemodynamic imaging capabilities of Doppler OCT and spectral microscopy to provide a comprehensive
picture of the pharmacodynamic effects of molecular cancer therapies in human cells grown into tumors in
the mouse window chamber. The first aim will use a combined spectral / OCT microscope lo quantify
changes in metabolic rate and hemodynamics with tumor growth. The second aim will develop photothermal
OCT for in vivo imaging of cell receptors, and will quantify the pharmocodynamics of receptor inhibition in the
mouse window chamber. The final aim will combine OCT and microscopy to quantify longitudinal changes in
receptor expression and hemodyanmic / metabolic response to combination therapies in mouse window
chamber tumors. These studies will establish our novel hemodynamic, metabolic and molecular imaging
techniques as high resolution, three-dimensional drug screening methods for preclinical applications. This
multi-disciplinary environment will provide an excellent opportunity for professional growth and scientific
advancement.
分子信号传导是癌症中的关键治疗靶标,并且分子治疗已经取得了一些进展。
成功治疗多种癌症。然而,我们对药效学效应的不完全认识,
限制了这些分子疗法的成功。我们最近开发了一种新的分子成像技术
技术,光热光学相干断层扫描(OCT),它扩展了穿透深度的高
分辨率超过显微镜极限的分子成像。目前的建议将进一步发展
光热OCT用于细胞受体的体内成像,并将联合收割机这种新技术与
多普勒OCT和光谱显微镜的血流动力学成像能力,
分子癌症疗法在生长成肿瘤的人类细胞中的药效学效应图,
老鼠的窗户第一个目标将使用组合的光谱/ OCT显微镜来量化
代谢率和血流动力学随肿瘤生长的变化。第二个目标是开发光热
OCT用于细胞受体的体内成像,并将量化在细胞中受体抑制的药效学。
小鼠窗口室。最终的目标是将联合收割机和显微镜相结合,以量化纵向变化,
小鼠窗口中受体表达和对联合治疗的血流动力学/代谢反应
腔室肿瘤这些研究将建立我们新的血流动力学、代谢和分子成像
高分辨率的三维药物筛选技术,用于临床前应用。这
多学科的环境将提供专业成长和科学的绝佳机会
进步。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Three-dimensional molecular imaging with photothermal optical coherence tomography.
- DOI:10.1007/978-1-62703-468-5_7
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:Skala, Melissa C;Crow, Matthew J;Wax, Adam;Izatt, Joseph A
- 通讯作者:Izatt, Joseph A
In vivo photothermal optical coherence tomography of endogenous and exogenous contrast agents in the eye.
内源性和外源性对比剂的体内光热光学相干断层扫描。
- DOI:10.1038/s41598-017-10050-5
- 发表时间:2017-08-23
- 期刊:
- 影响因子:4.6
- 作者:Lapierre-Landry M;Gordon AY;Penn JS;Skala MC
- 通讯作者:Skala MC
In vivo photothermal optical coherence tomography of gold nanorod contrast agents.
- DOI:10.1364/boe.3.002881
- 发表时间:2012-11-01
- 期刊:
- 影响因子:3.4
- 作者:Tucker-Schwartz JM;Meyer TA;Patil CA;Duvall CL;Skala MC
- 通讯作者:Skala MC
Dual-modality photothermal optical coherence tomography and magnetic-resonance imaging of carbon nanotubes.
- DOI:10.1364/ol.37.000872
- 发表时间:2012-03-01
- 期刊:
- 影响因子:3.6
- 作者:Tucker-Schwartz JM;Hong T;Colvin DC;Xu Y;Skala MC
- 通讯作者:Skala MC
Cross-sectional tracking of particle motion in evaporating drops: flow fields and interfacial accumulation.
- DOI:10.1021/la400542x
- 发表时间:2013-05-28
- 期刊:
- 影响因子:0
- 作者:Trantum JR;Eagleton ZE;Patil CA;Tucker-Schwartz JM;Baglia ML;Skala MC;Haselton FR
- 通讯作者:Haselton FR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melissa Caroline Skala其他文献
Melissa Caroline Skala的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melissa Caroline Skala', 18)}}的其他基金
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
用于视网膜成像的光热光学相干断层扫描的开发和验证
- 批准号:
10550200 - 财政年份:2022
- 资助金额:
$ 23.95万 - 项目类别:
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
用于视网膜成像的光热光学相干断层扫描的开发和验证
- 批准号:
10380391 - 财政年份:2022
- 资助金额:
$ 23.95万 - 项目类别:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
胰腺癌类器官的光学成像用于药物开发和个性化治疗
- 批准号:
9388210 - 财政年份:2017
- 资助金额:
$ 23.95万 - 项目类别:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
胰腺癌类器官的光学成像用于药物开发和个性化治疗
- 批准号:
10223218 - 财政年份:2017
- 资助金额:
$ 23.95万 - 项目类别:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
胰腺癌类器官的光学成像用于药物开发和个性化治疗
- 批准号:
9769226 - 财政年份:2017
- 资助金额:
$ 23.95万 - 项目类别:
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
(PQ7) 肿瘤异质性的定量体内光学成像
- 批准号:
9323359 - 财政年份:2016
- 资助金额:
$ 23.95万 - 项目类别:
Cellular level optical metabolic imaging to predict drug response in cancer
细胞水平光学代谢成像预测癌症药物反应
- 批准号:
9298127 - 财政年份:2014
- 资助金额:
$ 23.95万 - 项目类别:
Cellular level optical metabolic imaging to predict drug response in cancer
细胞水平光学代谢成像预测癌症药物反应
- 批准号:
9767107 - 财政年份:2014
- 资助金额:
$ 23.95万 - 项目类别:
Cellular level optical metabolic imaging to predict drug response in cancer
细胞水平光学代谢成像预测癌症药物反应
- 批准号:
9138626 - 财政年份:2014
- 资助金额:
$ 23.95万 - 项目类别:
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
用于监测癌症耐药性的功能光学相干断层扫描
- 批准号:
8128195 - 财政年份:2010
- 资助金额:
$ 23.95万 - 项目类别:
相似海外基金
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
- 批准号:
10733315 - 财政年份:2023
- 资助金额:
$ 23.95万 - 项目类别:
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival
SQLE 和甾醇导致 ER 乳腺癌患者生存率的种族差异
- 批准号:
10571020 - 财政年份:2023
- 资助金额:
$ 23.95万 - 项目类别:
Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.
建立组件的工业化生产,使癌症患者群体能够更容易地获得 PET 成像。
- 批准号:
10698218 - 财政年份:2023
- 资助金额:
$ 23.95万 - 项目类别:
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft Models
华盛顿大学 PDX 开发和试验中心 - Abemaciclib 联合 Olaparib 在卵巢癌和乳腺癌患者异种移植模型中的评估
- 批准号:
10582164 - 财政年份:2022
- 资助金额:
$ 23.95万 - 项目类别:
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
- 批准号:
10039823 - 财政年份:2022
- 资助金额:
$ 23.95万 - 项目类别:
EU-Funded
Convening a gynecologic cancer patient advisory group to adapt a digital health tool
召集妇科癌症患者咨询小组以采用数字健康工具
- 批准号:
460767 - 财政年份:2022
- 资助金额:
$ 23.95万 - 项目类别:
Miscellaneous Programs
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
- 批准号:
10038000 - 财政年份:2022
- 资助金额:
$ 23.95万 - 项目类别:
EU-Funded
Longitudinal mixed method investigation of social networks and affective states as determinants of smoking behavior among cancer patient
社会网络和情感状态作为癌症患者吸烟行为决定因素的纵向混合方法调查
- 批准号:
10513670 - 财政年份:2021
- 资助金额:
$ 23.95万 - 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
- 批准号:
10598311 - 财政年份:2021
- 资助金额:
$ 23.95万 - 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
- 批准号:
10442585 - 财政年份:2021
- 资助金额:
$ 23.95万 - 项目类别: